1 unchanged sentence
During the period covered by this Quarterly Report, none of the Company’s directors or executive officers has adopted or terminated a Rule 10b5 - 1 trading arrangement or a non-Rule 10b5 - 1 trading arrangement (each as defined in Item 408 of Regulation S-K under the Securities Exchange Act of 1934, as amended).
+Added: During the quarter ended March 31, 2025, we terminated certain licenses related to WP1122 with MD Anderson and are in discussions to execute an option or options on these technologies along with additional technologies where the term of such options will be tied to the term of our Sponsored Research Agreement with MD Anderson.
+Added: Such actions are in line with our efforts to focus our resources on the development of Annamycin.
+Added: The terminated license agreements consist of:
+Added: (i) the Patent and Technology License Agreement dated April 2, 2012 by and between The Board of Regents of the University of Texas System and IntertechBio Corporation, as amended;
+Added: (ii) the Patent And Technology License Agreement dated December 3, 2021 by and between The Board of Regents of The University Of Texas System on behalf of The University Of Texas M.
+Added: Anderson Cancer Center and Moleculin Biotech, Inc.;
+Added: and (iii) Patent and Technology License Agreement dated October 21, 2022 by and between The Board of The University Of Texas System on behalf of The University Of Texas M.D.
+Added: Anderson Cancer Center and Moleculin Biotech, Inc.
On November 4, 2024, the Compensation Committee of the Board of Directors took the following actions in connection with the executive compensation for the 2023/2024 compensation year ( June 1, 2023 to May 31, 2024) with its named executive officers (Walter Klemp, President and Chief Executive Officer;
3 unchanged sentences
and (ii) the Compensation Committee agreed that the accrued bonuses will earn interest at a rate of 8% per annum.
−Removed: On November 4, 2024, the Compensation Committee and the Board of Directors agreed to issue each non-employee director a 10 -year option to purchase 10,000 shares of our common stock, under our shareholder approved stock plan, with vesting through the end of April 2025 and an exercise price equal the closing price of our common stock on the date of the approval.
−Removed: Engagement Agreement between Moleculin Biotech, Inc.
−Removed: Wainwright & Co., LLC dated June 8, 2024 (incorporated by reference to Exhibit 1.1 of the Form S-1/A filed August 15, 2024)
−Removed: Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.9 of the Form S-1/A filed August 15, 2024)
−Removed: Form of Series A Common Warrant (incorporated by reference to Exhibit 4.10 of the Form S-1/A filed August 15, 2024)
−Removed: Form of Series B Common Warrant (incorporated by reference to Exhibit 4.11 of the Form S-1/A filed August 15, 2024)
−Removed: Form of Placement Agent Warrant (incorporated by reference to Exhibit 4.12 of the Form S-1/A filed August 15, 2024)
−Removed: Form of Securities Purchase Agreement incorporated by reference to Exhibit 10.32 of the Form S-1/A filed August 15, 2024)
−Removed: Form of Warrant Amendment Agreement (incorporated by reference to Exhibit 10.2 of the 8-K filed August 16, 2024)
+Added: In April 2025, the Company paid 50% of the executive bonuses and accrued interest from the 2023/2024 compensation year ( June 1, 2023 to May 31, 2024).
+Added: Form of Inducement Warrant (incorporated by reference to Exhibit 4.1 of the Form 8-K filed February 13, 2025)
+Added: Form of Pre-Funded Warrant in February 2025 offering (incorporated by reference to Exhibit 4.1 of the Form 8-K filed February 26, 2025)
+Added: Form of Common Warrant in February 2025 offering (incorporated by reference to Exhibit 4.2 of the Form 8-K filed February 26, 2025)
+Added: Form of Waiver agreement dated February 9, 2025 (incorporated by reference to Exhibit 10.35 of the Form S-1 file number 333-283820)
+Added: Form of Inducement Letter (incorporated by reference to Exhibit 10.1 of the 8-K filed February 13, 2025)
+Added: Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 of the 8-K filed February 26, 2025)
+Added: Placement Agency Agreement between Moleculin Biotech, Inc.
+Added: and Roth Capital Partners, LLC (incorporated by reference to Exhibit 10.2 of the 8-K filed February 26, 2025)
Certification of Principal Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002
16 unchanged sentences
MOLECULIN BIOTECH, INC.
−Removed: November 8 , 2024
+Added: May 13 , 2025
/s/ Walter V.
1 unchanged sentence
(Principal Executive Officer)
−Removed: November 8 , 2024
+Added: May 13 , 2025
/s/ Jonathan P.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.